International registry for very rare childhood tumors
The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.
Azienda Ospedaliera di Padova · NCT07072143
This project will collect detailed medical information to see how clinical and biological features affect outcomes in children and adolescents with very rare tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6250 (estimated) |
| Ages | 0 Years to 18 Years |
| Sex | All |
| Sponsor | Azienda Ospedaliera di Padova (other) |
| Locations | 1 site (Padova, Italy) |
| Trial ID | NCT07072143 on ClinicalTrials.gov |
What this trial studies
The PARTNER initiative is a prospective, observational international registry that gathers epidemiological, clinical, biological, radiological, and treatment data on children and adolescents with very rare tumors. It enrolls patients aged 0–18 with primary or relapsed malignancies that are very rare in childhood and requires written informed consent from patients or guardians. The study does not assign any experimental treatments and is run as a non-profit effort led by Padua University Hospital with collaborating European centers in the EXPeRT network. By pooling standardized data across countries, the project aims to improve diagnostic criteria and inform future treatment recommendations for these understudied tumor types.
Who should consider this trial
Good fit: Children and adolescents aged 0–18 with a primary or relapsed very rare tumor (typically incidence <2 per million per year) who are diagnosed or treated at a participating center and who provide written informed consent are eligible.
Not a fit: Patients older than 18, those with common tumor types, those not treated at participating centers, or those who do not provide consent are unlikely to gain direct benefits from this observational data collection and will not receive experimental therapies through the project.
Why it matters
Potential benefit: If successful, the registry could improve future diagnosis and treatment recommendations and ultimately help improve outcomes for children with very rare tumors.
How similar studies have performed: Previous international registries and collaborative networks have produced modest gains in knowledge and care for some rare pediatric cancers, so this project builds on prior collaborative experience rather than introducing an untested concept.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center. * Written informed consent from the patient and/or the parent/legal guardian Exclusion Criteria: * Absence of Written informed consent from the patient and/or the parent/legal guardian
Where this trial is running
Padova, Italy
- Pediatric Oncology Unit, University Hospital Padova [AOUP Azienda Ospedale Università Padova] — Padova, Italy, Italy (RECRUITING)
Study contacts
- Principal investigator: Gianni Bisogno, MD — Azienda Ospedale Università Padova - Italy
- Study coordinator: Gianni Bisogno, MD
- Email: gianni.bisogno@unipd.it
- Phone: 0039 0498211481
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor, Adrenocortical Tumor, Pancreatic Tumors, Esthesioneuroblastoma, Olfactory, Mesothelioma, Nasopharyngeal Carcinoma